{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:53:49Z","timestamp":1777557229634,"version":"3.51.4"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T00:00:00Z","timestamp":1402272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0098961","type":"journal-article","created":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T20:40:06Z","timestamp":1402346406000},"page":"e98961","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":87,"title":["Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study"],"prefix":"10.1371","volume":"9","author":[{"given":"Yen-Chieh","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruey-Meei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jou-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hsuin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Shu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,6,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","article-title":"Neuropathology of Parkinson's disease","volume":"55","author":"LS Forno","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson's disease","author":"P Jenner","year":"2003","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","article-title":"Mitochondria in the aetiology and pathogenesis of Parkinson's disease","volume":"7","author":"AH Schapira","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-012-1004-6","article-title":"Protein degradation pathways in Parkinson's disease: curse or blessing","volume":"124","author":"D Ebrahimi-Fakhari","year":"2012","journal-title":"Acta Neuropathol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"G Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/HYPERTENSIONAHA.111.171249","article-title":"Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study","volume":"57","author":"C Qiu","year":"2011","journal-title":"Hypertension"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"\u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson's disease","volume":"447","author":"CS Chan","year":"2007","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1474-4422(07)70246-6","article-title":"Calcium, ageing, and neuronal vulnerability in Parkinson's disease","volume":"6","author":"DJ Surmeier","year":"2007","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0006-8993(96)00917-1","article-title":"1-Methyl-4-phenyl- 1,2,3,6- tetrahydropyridine induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level","volume":"741","author":"A Kupsch","year":"1996","journal-title":"Brain Res"},{"key":"ref10","article-title":"Importance of the brain Angiotensin system in Parkinson's disease","author":"JW Wright","year":"2012","journal-title":"Parkinsons Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","article-title":"Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES)","volume":"33","author":"ED Louis","year":"2009","journal-title":"Neuroepidemiology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2006.03.004","article-title":"Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism","volume":"51","author":"A Mu\u00f1oz","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease","volume":"30","author":"KA Reardon","year":"2000","journal-title":"Aust N Z J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-2-1","article-title":"Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra","volume":"2","author":"TN Grammatopoulos","year":"2007","journal-title":"Mol Neurodegener"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1742-2094-9-38","article-title":"Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease","volume":"9","author":"P Garrido-Gil","year":"2012","journal-title":"J Neuroinflammation"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and Parkinson's disease","volume":"175","author":"B Pasternak","year":"2012","journal-title":"Am J Epidemiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"C Becker","year":"2008","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and Parkinson's disease","volume":"175","author":"B Pasternak","year":"2012","journal-title":"Am J Epidemiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"B Ritz","year":"2010","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/mds.23191","article-title":"Calcium channel blocker use and risk of Parkinson's disease","volume":"25","author":"KC Simon","year":"2010","journal-title":"Mov Disord"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and beta-blockers in relation to Parkinson's disease","volume":"13","author":"TG Ton","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2125.1981.tb01169.x","article-title":"Beta-adrenoceptor blockers and the blood-brian barrier","volume":"11","author":"G Neil-Dwyer","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIRCULATIONAHA.107.183885","article-title":"Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention","volume":"115","author":"C Rosendorff","year":"2007","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0929-6646(10)60120-9","article-title":"2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension","volume":"109","author":"CE Chiang","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.22616","article-title":"Dihydropyridine calcium channel blockers and the progression of parkinsonism","volume":"71","author":"C Marras","year":"2012","journal-title":"Ann Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2337\/dc10-1333","article-title":"Diabetes and the risk of developing Parkinson's disease in Denmark","volume":"34","author":"E Schernhammer","year":"2011","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"d198","DOI":"10.1136\/bmj.d198","article-title":"Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study","volume":"342","author":"JA Driver","year":"2011","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"ML Wahlqvist","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/01.wnl.0000286942.14552.51","article-title":"Statin use and the risk of Parkinson disease","volume":"70","author":"AD Wahner","year":"2008","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1212\/WNL.0b013e31829d873c","article-title":"Discontinuation of statin therapy associates with Parkinson disease: a population-based study","volume":"81","author":"YC Lee","year":"2013","journal-title":"Neurology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0098961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T15:20:21Z","timestamp":1716823221000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0098961"}},"subtitle":[],"editor":[{"given":"Ryuichi","family":"Morishita","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,9]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0098961","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,9]]}}}